نتائج البحث

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

• Authors : Eli Lilly and Company

• Source: A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

تفاصيل العنوان

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

• Source: A Phase 1/1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of LP-118 in Subjects With Relapsed or Refractory Hematological Malignancies

تفاصيل العنوان

Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study.

• Authors : Wierda, William G; Jacobs, Ryan; Barr, Paul M

Subjects: Biomedical and Clinical Sciences; Oncology and Carcinogenesis; Clinical Research

• Source: Journal of Clinical Oncology. 42(16_suppl)

تفاصيل العنوان

Ohlédnutí za čtvrtstoletím léčby chronické lymfocytární leukemie.

• Authors : Papajík, T. (AUTHOR); Urbanová, R. (AUTHOR); Turcsányi, P. (AUTHOR)

• Source: Transfusiology & Haematology Today / Transfuze a Hematologie Dnes. 2019, Vol. 25 Issue 1, p72-80. 9p.

تفاصيل العنوان

Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) (ACALLO)

• Authors : AstraZeneca

• Source: Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)

تفاصيل العنوان

Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

• Authors : German CLL Study Group

• Source: A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (GS-4059) and Idelalisib With and Without Obinutuzumab in Subjects With

تفاصيل العنوان

Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL

• Source: A Phase I, Open-label, Dose-escalation Study to Assess the Safety, Tolerability and Efficacy of the Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory

تفاصيل العنوان

Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment

• Authors : Stichting Hemato-Oncologie voor Volwassenen Nederland; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Karolinska Institutet ...

• Source: Short-term Combined Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection and/or Early Treatment, Who do Not Fulfil IWCLL

تفاصيل العنوان

Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL (ThRiL)

• Authors : Celgene

• Source: A Phase II Study of Daily Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL

تفاصيل العنوان

Prognostic impact of serum 25-hydroxivitamin D [25(OH)D] concentrations in patients with lymphoid malignancies.

• Authors : Aref, Salah¹ (AUTHOR) ; Ibrahim, Lamiaa¹ (AUTHOR); Azmy, Emaad² (AUTHOR)

• Source: Hematology. Jan2013, Vol. 18 Issue 1, p20-25. 6p.

تفاصيل العنوان